Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Ann Oncol8099 passages
• Center (DKFZ), Heidelberg, GermanyCorrespondence to: Prof.37 passages
• Center North, German Center of Lung Research, Grosshansdorf (M.R.), Germany;3 Department of Electrical Engineering, University of São Paulo, São Carlos, São Paulo, Brazil;4 Department of Internal23 passages
• Center n.a. N.N. Blochin of RAMS’, Moscow, Russia625 passages
• Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh6 Upstate Medical University, Syracuse, USACorrespondence to: Dr24 passages
• Center, The University of21 passages
• Centre, Churchill Hospital, Oxford, UK* Correspondence to: Dr55 passages
• Centre, Oxford, UKCorrespondence to: Dr25 passages
• Centre, Sheffield, UK3 Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria4 Department of Oncology, Novartis33 passages
• Centre, The Institute of Cancer Research, London, UK3 Clinical Oncology Department, British American Hospital, Lima, Peru4 Department of Medical Oncology, Christie21 passages
• Centre, The Institute of Cancer Research, London5 The Breast Cancer Now Research Unit, Guy’s Cancer Centre, Kings College, London6 The Royal36 passages
• Centre, University of Oxford, Oxford, UKCorrespondence to: Prof.27 passages
• CouncilAgency for Science, Technology and Research10.13039/501100001348Korean Health21 passages
• Data Management and Statistics Unit, The Royal28 passages
• Department of Pathology, University College London Medical School, London, UKCorrespondence to: Prof.21 passages
• ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe35 passages
• Editor's choiceESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†55 passages
• Group, Hungarian Academy of Sciences, 2nd Department of Pathology, Semmelweis University, Budapest,Hungary* Correspondence to: Prof. Charles Swanton, Cancer23 passages
• Institute and Honor Health, Scottsdale, USA* Correspondence to: Dr23 passages
• Institute of Pulmonology, Pavlov State Medical University, Saint Petersburg, Russia12 F. Hoffmann-La Roche, Basel, Switzerland* Correspondence to:24 passages
• Institute, Brisbane, QLD16 Royal Brisbane & Women’s Hospital, Pathology Queensland, Brisbane, QLD, AustraliaCorrespondence to: Dr26 passages
• Institute, Durham, NC, USA* Correspondence to: Prof.20 passages
• Institute, Melanoma Therapeutics, Los Angeles, USA8 Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori26 passages
• Institute, Nashville, USA* Correspondence to: Dr24 passages
• Institute, Nashville, USA22 Respiratory Oncology Unit, Department of Respiratory Medicine, University29 passages
• Institute, Nashville; 7 Tennessee Oncology, Nashville; 8 US Oncology Research/Comprehensive Cancer21 passages
• Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea10 Royal Marsden Hospital, Sutton, UK11 Hôpital Européen Georges Pompidou, Université22 passages
• Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment23 passages
• Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer25 passages
• Network, LLC, Omaha, USA * Correspondence to: Dr Oliver Sartor, Departments of Medicine and Urology,22 passages
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 201342 passages
• Precision MedicineLarotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study26 passages
• Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)54 passages
• Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer15 passages
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 201134 passages
• Switzerland S.A., Mendrisio, Switzerland12 sigma-tau Industrie Farmaceutiche32 passages
• Therapeutics (START) Center for Cancer Care, San Antonio2 University of Pittsburgh, Pittsburgh336 passages
• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 200934 passages
• UK & UCL Cancer Trials Centre, London2 Department of Oncology, UCL Medical School, Royal Free Campus, London3 Cancer21 passages
• UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge7 AstraZeneca, Gatehouse Park, Waltham, USA8 DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer22 passages
• UK Cambridge Institute, University of Cambridge, Cambridge8 Department of Oncology, University of Cambridge, Cambridge, UK* Correspondence to: Dr25 passages
• UK Centre, Southampton, UK * Correspondence to: Professor David Cunningham, Department of Medicine, The Royal22 passages
• UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UKCorrespondence to: Dr29 passages
• UK Clinical Trials Unit, University of Birmingham, Birmingham4 Department of Medicine, Royal21 passages
• UK Department of Cancer Medicine, Imperial College London, Hammersmith Hospitals Trust, London, UK* Correspondence to:29 passages
• UK Manchester Institute, Manchester2 The University of Manchester, The22 passages
• UK Manchester Institute, Manchester3 Experimental Pathology Laboratory, Cancer27 passages
• UK Manchester Institute, University of Manchester, Manchester, UK* Correspondence to: Prof. Richard Marais, Molecular Oncology Group, Cancer16 passages
• UK Manchester Institute, University of Manchester, Manchester5 The18 passages
• UK Postdoctoral FellowshipC42785/A17965Cancer38 passages
• UK http://dx.doi.org/10.13039/501100000289A18052European Union FP7334261National Institute for Health Research (NIHR)Biomedical Research Centre (BRC)The Royal17 passages
• UK’sExperimental Cancer Medicine CentreECMCCombinations’ AllianceInstitute of Cancer Research10.13039/501100000027The Royal MarsdenCambridge University24 passages
• Unit, Cambridge University20 passages
• Unit, Division of Haematology, Department of34 passages
• Unit, Institute of Clinical Trials Research, University of Leeds, Leeds2 Cambridge Cancer Trials Centre/Cambridge Clinical Trials Unit, Cancer Theme, Cambridge University17 passages
• Unit, San Gerardo Hospital, Monza, Italy3 University Hospital of the RWTH Aachen, AachenCorrespondence to: Dr39 passages
• Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM)23 passages